Home Latest News News Eine frühzeitige Diagnose verbessert die Prognose von jungen Rheumatikern
Research ticker |

Early diagnosis improves the prognosis of young people with rheumatic diseases

The DRFZ is running various long-term registers to monitor young patients with rheumatic diseases. Since 2007, the JuMBO biologics register has been providing important information on the long-term efficacy and tolerability of anti-rheumatic drugs in patients with juvenile idiopathic arthritis (JIA). The data on more than 1,500 young patients show that early intensive treatment improves the prognosis in adulthood. The more consistently JIA is treated from the outset, the more often patients achieve drug-free remission in young adulthood and the less often they have co-morbidities.

Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood.
Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, Foeldvari I, Haas JP, Klein A, Tatsis S, Tenbrock K, Zink A, Klotsche J.
Arthritis Care Res (Hoboken). 2019 Apr;71(4):471-481. doi: 10.1002/acr.23709.
PMID: 30044538
Paediatric Rheumatology Prof. Dr. med. Kirsten Minden Phone +49 (0)30 28460-669 minden@drfz.de more
Sign up for the
DRFZ NewsFlash